Avita Medical (RCEL) said late Tuesday it now expects Q4 commercial revenue of about $18.4 million, below its prior outlook range of $22.3 million to $24.3 million.

Full-year 2024 commercial revenue is now pegged at roughly $64.3 million, down from its previous range of $68 million to $70 million.

For 2025, the company expects commercial revenue between $100 million and $106 million. Avita said it now expects to achieve cash flow break-even and GAAP profitability in Q4 2025, instead the previously expected Q3 2025.

The company's shares were down more than 8% in after-hours activity.